NEW YORK (GenomeWeb) — Using PCR-based methods to detect mutations in the BCR-ABL1 kinase domain of chronic myeloid leukemia patients has been established as a critical tool for monitoring CML patient response to tyrosine kinase inhibitor therapy.

However, according to recent studies from Australian researchers, when PCR assays reveal the presence of a specific kind of mutation — so-called compound mutations, where more than one mutation occurs within the same BCR-ABL1 molecule — it may in fact be an artifact caused by PCR-mediated recombination.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.

Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.

In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.

Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.